DGX Forensic analysis

HOLDConviction: 6/10Price: $190.3910-Q
Loading technical data…

Price Targets (12m)

Bull Case
$220.00
+15.6% from current
Base Case
$198.00
+4.0% from current
Bear Case
$175.00
-8.1% from current

Detailed research

PART 1: TRADING EXECUTION

Trading Setup & Entry Strategy

Quest Diagnostics (DGX) is currently in a BEARISH_CROSSING phase, hovering near its 200-day SMA ($187.62). The stock is exhibiting weakness, having declined 7.14% over the last 20 days. Given the lack of a clear bullish catalyst and the technical breakdown, we are prioritizing capital preservation.

  • >Entry Zone: WAIT. We are looking for a retest of the $183.00 - $184.00 support level. If the stock holds above $183.71 (Lower Bollinger Band), it presents a swing trade opportunity.
  • >Stop Loss: HARD stop at $179.50, providing a buffer below the recent technical floor.
  • >Position Sizing: Limit to 2% of total portfolio given the current momentum volatility.
  • >Scaling Strategy: If $183.00 holds, initiate 50% position. Accumulate remaining 50% upon a confirmed bullish crossover of the 10-day SMA ($189.30).
  • >Take Profit: Target $195.00 (near 50-day SMA) and $200.00 (Upper Bollinger Band).

PART 2: DETAILED RESEARCH

Financial Health & Valuation

DGX posted a strong Q1 2026, with Net Revenues up 9.2% to $2.89B and EPS growth of 15.5%. However, Revenue per requisition fell 1.3%, signaling a mix shift toward lower-margin routine testing. While the balance sheet is stable, the Goodwill of $9.12B remains a high portion of total assets ($16.67B). The current forward growth expectation is moderate, and the stock is trading at a fair, though not screaming, value given the macro headwinds.

Technical Analysis

  • >Trend: BEARISH_CROSSING. Price is trading below the 50-day SMA ($194.96).
  • >Momentum: RSI is 46.53 (Neutral), suggesting the stock is neither overextended to the upside nor deeply oversold.
  • >Reconciliation: The fundamental strength (solid cash flow/dividends) conflicts with the short-term bearish price action. We treat this as a Value Trap scenario until the price reclaims the 50-day SMA.

Short-Term Trading Strategy (2-5 Days)

  • >Timeframe: Swing Trade (2–5 Days)
  • >Risk/Reward: Targeted 1:2.3.
  • >Catalyst: Monitor for any sector-wide rebound in the lab services space or unexpected M&A headlines.
  • >Constraint: Exit immediately if the price closes below $182.00.

Thesis: DGX is a high-quality cash generator currently undergoing a technical correction. We are waiting for the 'washout' at the $184 level before re-engaging with a defensive long posture.


Investment Recommendation

HOLD. The technicals are currently failing to support the fundamentals. Wait for the $183 support validation.